Drug intelligence / Profile preview

gallium (68Ga) vipivotide tetraxetan

Development stage: Unknown
Lead developer: Advanced Accelerator Applications
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
Administration: Intravenous

Overview

Ga68-PSMA-617 (gallium (68Ga) vipivotide tetraxetan) is a radiolabeled diagnostic agent used in positron emission tomography (PET) imaging. It consists of the small-molecule targeting ligand vipivotide tetraxetan (PSMA-617), which binds with high affinity to the extracellular domain of prostate-specific membrane antigen (PSMA), conjugated to the positron-emitting radioisotope gallium-68 (68Ga). PSMA is a transmembrane glycoprotein that is highly overexpressed on prostate cancer cells, particularly in advanced, metastatic, and castration-resistant stages. Upon intravenous administration, Ga68-PSMA-617 selectively accumulates in PSMA-expressing tumor lesions, allowing for high-resolution PET/CT or PET/MRI imaging to detect primary prostate cancer, localize metastases, and identify patients eligible for PSMA-targeted radioligand therapies, such as lutetium (177Lu) vipivotide tetraxetan (Pluvicto).

Other names: 68Ga-Psma-61768Ga-vipivotide tetraxetanPSMA-617 Ga-68PSMA617 Ga-68PSMA 617 Ga-68gallium Ga 68-PSMA-617gallium Ga 68 vipivotide tetraxetangallium-68 PSMA-617gallium68 PSMA-617gallium 68 PSMA-617gallium-68 vipivotide tetraxetangallium68 vipivotide tetraxetangallium 68 vipivotide tetraxetanvipivotide tetraxetan gallium ga-68

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on gallium (68Ga) vipivotide tetraxetan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallium (68Ga) vipivotide tetraxetan.